About Inflammatix
our mission
Inflammatix is on a bold mission to help bring about a new era in emergency and critical care.
Our tests decode the body’s host immune response to reveal new insights, once thought beyond reach, for conditions like pneumonia and sepsis. Just like testing for troponin helped to redefine care for heart attacks, our molecular diagnostics will give healthcare providers the clarity they need to make faster, better decisions. Inflammatix is setting the stage for better patient outcomes and more resilient health systems—building a future where urgent and critical care is as responsive and effective as can be.
Precision medicine on demand
There is a critical unmet need for quickly and accurately characterizing infections in patients who are acutely ill. Our expert bioinformatics and assay development teams are building a host-response-based diagnostics pipeline that includes tests for acute infection and sepsis, emerging infectious diseases, autoimmune diseases, tropical infections, transplant rejection, and other conditions.
We initially developed TriVerity, a test for emergency department patients suspected of acute infection or sepsis using patent-pending immune response-based biomarkers exclusively licensed from Stanford University.

Leadership

Tim Sweeney, MD, PhD
Co-Founder and CEO

Jonathan Romanowsky
Co-Founder and Chief Business Officer

Purvesh Khatri, PhD
Co-Founder and Chief Scientist

Jamie Lewis
Chief Commercial Officer

Joao Fonseca, PhD
Chief Technology Officer

Sam Ajizian, MD
Chief Medical Officer

Mario Torres
Interim Chief Financial Officer

Martín Vazquez
Interim Chief Operating Officer

Christopher MacGriff, PhD
Vice President of Strategy and Corporate Development

Diana Lane
Vice President of Quality Assurance and Regulatory Affairs

Ljubomir Buturovic, PhD
Vice President of Machine Learning

Paul Fleming, PhD
Vice President of Engineering and Program Management

Tawny Darling
Vice President of People Operations

Kulwant Sandhu
Vice President, Integrated Supply Chain
Board of Directors

Lucy Coassin
Director, Northpond Ventures

Heiner Dreismann, PhD
Former CEO, Roche Molecular Systems

Florian Kainzinger, PhD
Founder, Think.Health Ventures

David Persing, MD, PhD
EVP/Chief Medical Officer, Cepheid

Jonathan Romanowsky
Co-Founder and Chief Business Officer

Tim Sweeney, MD, PhD
Co-Founder and CEO

Steve Tablak
Former Chairman and CEO, GeneWeave
Board of Advisors

Laura L. Adams
Special Advisor at the National Academy of Medicine (NAM)

Jim Ducharme
Clinical Professor of Medicine

Oliver Liesenfeld
Retired CMO, Infectious Diseases and Diagnostic Devices
In Memorium
In memory of our valued scientific advisory board member and close friend

Hector Wong, MD
Professor of Pediatrics
Partner with Us!
Inflammatix is establishing partnerships with diagnostic instrument, companion therapeutic and commercial distribution companies across the globe. Connect with us at info[at]inflammatix.com to explore collaboration opportunities.
Inflammatix projects have been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50119C00034.
Awards
Inflammatix is recognized for our accomplishments and promise

2024 Red Dot Award
Design Concept |
Ready For Market |
Artificial Intelligence

2024 UX Design Award

2024 Congressional Innovation Showcase on Intersection between AI and Health Equity

2023 FDA Breakthrough Device Designation

2021 SCCM Gold Snapshot Award for the 50th Critical Care Congress

Tracxn Emerging Startups 2021: Top Diagnostics Tech Startups

2020 MedTech Innovator Top 50 Medtech Startups

2019 FierceMedTech Fierce 15 Company

2019 AACC Disruptive Technology and Audience Choice Awards